IBRX280121C00003500
IBRX Jan 21 2028 3.50 Call
optionOPRA
EODOct 14, 2026
7.10USD+1.865%(+0.13)10Vol27,275OI
Loading…
Underlying
Underlying Price
$8.48
Type
Call
Strike
3.5
Expiration
Jan 21, 2028
DTE
458d
Moneyness
ITM
Intrinsic
$4.98
IBRX 3.5 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | $6.49 | -0.61% | 1 | 11 |
| Oct 30, 2026 | 10d | $5.80 | +20.83% | 2 | 3 |
| Nov 6, 2026 | 17d | $6.60 | +3.45% | 8 | 24 |
| Nov 13, 2026 | 24d | — | — | 0 | 0 |
| Jan 15, 2027 | 87d | $6.54 | -7.23% | 4 | 4,158 |
| Jan 21, 2028 | 458d | $7.10 | +1.87% | 10 | 27,275 |
IBRX Nearby Strikes · Jan 21, 2028
| Strike | Last | Change | Vol | Open Int | Moneyness |
|---|---|---|---|---|---|
| .5 C | $8.93 | -4.18% | 2 | 128 | ITM |
| 1 C | $9.25 | -2.63% | 1 | 75 | ITM |
| 1.5 C | $8.25 | +18.36% | 5 | 38 | ITM |
| 2 C | $7.90 | -10.63% | 4 | 5,401 | ITM |
| 2.5 C | $7.40 | -7.50% | 6 | 15,793 | ITM |
| 3 C | $6.50 | -16.13% | 1 | 31,197 | ITM |
| 3.5 C | $7.10 | +1.87% | 10 | 27,275 | ITM |
| 4 C | $6.75 | -1.75% | 15 | 2,170 | ITM |
| 4.5 C | $6.65 | +2.78% | 2 | 380 | ITM |
| 5 C | $5.44 | -11.54% | 4,002 | 12,523 | ITM |
| 5.5 C | $5.21 | -12.14% | 2 | 3,508 | ITM |
| 7.5 C | $4.20 | -10.64% | 9,831 | 18,015 | ITM |
| 10 C | $3.20 | -14.44% | 677 | 10,691 | OTM |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.